Metastatic Advanced Pancreas Sorafenib

Study ID
NCT00758381

Study type
Interventional

Study phase
Phase 2

Study status
Unknown status

Trial Acronym

MAPS

Trial Summary

This is multicentre, open-label, randomized, phase II trial in patients with locally advanced or metastatic pancreatic cancer. Subjects will be randomized in a 1:1 ratio to receive gemcitabine/cisplatin in combination with Sorafenib (arm A) or gemcitabine/cisplatin alone (arm B), as first-line chemotherapy.

More informations

Trial Starting Date

Aug 31,2007

Requirements

Gender All
Minimum age 18 Years
Maximum age 75 Years

Enrollement Limit

114